This is the largest real-world study to date involving the administration of LHRH agonists in Chinese patients with prostate cancer, demonstrating the effectiveness and safety of long-acting goserelin 10.8-mg depot, which was administered to 97.6% of patients in this study. Here, GNRH1 is linked to prostate cancer.